Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)

NCT00359450 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

186

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: BMS-275183 (oral taxane)

Sponsor

Bristol-Myers Squibb